Overview

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Asunaprevir